R. Dilcher, C. Malpas, Stuart J. McDonald, W. O’Brien, C. Despott*, K. Bertram, M. P. Pase, Lukas Frontzkowski, Meng Law, Terence J O'Brien, L. Vivash
tlooto Summary
Fluid biomarkers, complemented by PET and MRI, may support multimodal PSP diagnosis, monitoring, and trial stratification.
Abstract
OBJECTIVE Identifying objective biomarkers for progressive supranuclear palsy (PSP) is crucial to improving diagnosis and establishing clinical trial and treatment endpoints. This study evaluated fluid biomarkers in PSP versus controls and their associations with regional 18F-PI-2620 tau-PET, clinical, and cognitive outcomes.
METHODS Twenty-four PSP patients and 11 age- and sex-matched control subjects underwent Cerebrospinal fluid (CSF) and plasma assays of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), and total tau (t-tau) using SIMOA. Ratios (NfL/t-tau, GFAP/t-tau, GFAP/NfL) were calculated. Tau burden was quantified using PI-2620 distribution volume ratio (DVR). Group comparisons and associations with tau-PET, MRI, and cognition were tested using Wilcoxon tests, ROC analyses, and age- and sex-adjusted linear models.
RESULTS PSP patients showed elevated NfL, GFAP levels, and higher NfL/t-tau and GFAP/t-tau ratios in CSF and plasma. CSF NfL/t-tau best discriminated PSP from control subjects (AUC = 0.99, 95% CI [0.97-1.00]; optimal cut-off: > 10), followed by CSF GFAP/t-tau (AUC = 0.89, 95% CI [0.76-1.00]; > 104) and plasma NfL/t-tau (AUC = 0.80, 95% CI [0.63-0.96]; 5.1). Plasma NfL/t-tau correlated with tau-PET DVR in the putamen (β = 0.63; 95% CI [0.15-1.11]; p < 0.01) and pallidum (β = 0.54, 95% CI [0.07-1.02]; p < 0.01) and predicted disease severity (β = 0.61, 95% CI [0.19, 1.04]; p = 0.007) and processing speed (β = 0.66, 95% CI [0.22, 1.10]; p = 0.006), explaining 35% and 33% of variance, respectively. Frontal MRI volume modestly improved prediction of processing speed (ΔR2adj = 0.23, p = 0.01), whereas tau-PET did not.
INTERPRETATION Plasma NfL/t-tau correlates with regional tau, disease severity, and cognition. Fluid biomarkers, complemented by PET and MRI, may support multimodal PSP diagnosis, monitoring, and trial stratification.
TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry: ACTRN12620001254987.
Citation format
DILCHER, R., et al. Fluid biomarkers of disease burden and cognitive dysfunction in progressive supranuclear palsy. Annals of Clinical and Translational Neurology, 2026, 13(7): 1422–1432.